Salud financiera de hoja de balance de SELLAS Life Sciences Group

Salud financiera controles de criterios 4/6

SELLAS Life Sciences Group tiene un patrimonio de los accionistas total de $15.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $26.5M y $10.6M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$21.03m
Patrimonio	US$15.89m
Total pasivo	US$10.61m
Activos totales	US$26.51m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($24.0M) de RXK3 superan a sus pasivos a corto plazo ($10.6M).

Pasivo a largo plazo: RXK3 no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: RXK3 está libre de deudas.

Reducción de la deuda: RXK3 no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RXK3 tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: RXK3 tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 9.2% cada año

Salud financiera de hoja de balance de SELLAS Life Sciences Group

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Recent updates

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

New major risk - Financial position

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S

New major risk - Negative shareholders equity

SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

New major risk - Financial position

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid Leukemia

Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

Full year 2022 earnings released: US$2.13 loss per share (vs US$1.34 loss in FY 2021)

SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer

SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality

SELLAS Life Sciences Group, Inc. Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies

SELLAS Life Sciences Group, Inc. ’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vivo Study

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)

Insufficient new directors

SELLAS Life Sciences Group, Inc. Announces Update on Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (Pembrolizumab) in Patients with Wt1+ Platinum-Resistant Advanced Ovarian Cancer

SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S

Insufficient new directors

SELLAS Life Sciences Group Announces Results from New Preclinical in Vitro Study for its Highly Selective CDK9 Inhibitor, GFH009

SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021)

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vitro Studies for CDK9 inhibitor, GFH009

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

SELLAS Life Sciences Group, Inc. Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

SELLAS Life Sciences Group, Inc. Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.16 loss in 1Q 2021)

Insufficient new directors

SELLAS Life Sciences Group, Inc. Launches Expand Access Program for Galinpepimut-S

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 08, 2022

SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study

Sellas Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

Sellas Life Sciences Group, Inc. Announces Final Court Approval of Settlement of Securities Litigation

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

SELLAS Life Sciences Group, Inc. Announces IND Acceptance for First Clinical Trial of GPS in China

SELLAS Life Sciences Group, Inc. Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer

SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo

Forecast breakeven pushed back to 2024

Forecast breakeven pushed back to 2024

Sellas Life Sciences Group, Inc. Announces Executive Changes

Sellas Life Sciences Group, Inc. Announces Promising Initial Clinical Data for Galinpepimut-S (Gps) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications

SELLAS Life Sciences Group, Inc. Announces Positive Follow-Up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast